Welcome to our dedicated page for Nautilus Biotechnology SEC filings (Ticker: NAUT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nautilus Biotechnology filings document SEC reporting for a Nasdaq-listed life sciences tools company developing single-molecule proteome analysis technology. Recent Form 8-K reports furnish quarterly and annual financial results and record material events, including continued-listing compliance with Nasdaq rules.
Proxy materials cover annual meeting procedures, director elections, stockholder voting matters, and board governance. The filings also identify the company's registered common stock under ticker NAUT and provide formal records of its capital structure, governance actions, and public-company reporting obligations.
Andreessen Horowitz–affiliated funds filed an amended Schedule 13D for Nautilus Biotechnology to reflect recent share sales and updated holdings. AH Bio Fund II and Andreessen Horowitz LSV Fund II sold 4,615,974 and 384,026 Nautilus common shares, respectively, on June 2, 2026 in a single block trade at $2.35 per share.
After these transactions, Marc Andreessen and Benjamin Horowitz are each reported to beneficially own 12,653,917 shares, representing approximately 9.96% of Nautilus’s common stock based on 127,078,855 shares outstanding as of April 23, 2026, though EDGAR cover pages round this to 9.9%. The filing details their sole and shared voting and dispositive powers through various venture funds and general partner entities.
Nautilus Biotechnology, Inc. disclosed that investment funds affiliated with Andreessen Horowitz executed open-market sales of common stock. AH Bio Fund II, L.P. sold 4,615,974 shares of common stock at $2.35 per share, leaving 11,682,032 shares of common stock held indirectly. Andreessen Horowitz LSV Fund II, L.P. sold 384,026 shares of common stock at $2.35 per share, with 971,885 shares of common stock remaining indirectly held. The funds are controlled through general partners AH Equity Partners Bio II, L.L.C. and AH Equity Partners LSV II, L.L.C., whose managing members are Marc Andreessen and Ben Horowitz, and the reporting persons disclaim group status and beneficial ownership beyond any pecuniary interest.
Nautilus Biotechnology, Inc. is holding its 2026 annual stockholder meeting virtually on June 17, 2026 at 10:00 a.m. Pacific Time. Holders of common stock as of April 20, 2026, when 127,078,855 shares were outstanding, may attend and vote online using a 16‑digit control number.
Stockholders will vote on electing two Class II directors through 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving 2025 executive compensation on an advisory basis, and choosing how often to hold future say‑on‑pay votes. The board recommends voting for all proposals and selecting “one year” for say‑on‑pay frequency.
Nautilus Biotechnology reported a Q1 2026 net loss of $14.7 million, an improvement from $16.6 million a year earlier, as it continues developing its Nautilus Voyager proteomics platform with no product revenue yet. Research and development expenses fell to $9.7 million and selling, general and administrative costs declined to $6.4 million, reflecting prior cost reductions.
The company held $95.9 million in cash, cash equivalents and short‑term investments and $143.4 million including long‑term investments as of March 31, 2026, and believes this will fund operations for at least the next twelve months while it advances its Early Access Program and phased commercial launch planned for 2026–2027.
Nautilus Biotechnology reported first quarter 2026 results, showing lower spending and a narrower loss as it advances its proteomics platform toward commercialization. Operating expenses were $16.1 million, down 14% from $18.8 million a year earlier, mainly from lower salaries, stock-based compensation, and facilities costs.
Net loss improved to $14.7 million for the quarter, compared with $16.6 million in the prior-year period, or $0.12 per share versus $0.13. Cash, cash equivalents, and investments totaled $143.4 million as of March 31, 2026, supporting ongoing development of the Voyager platform and the new Iterative Mapping Early Access Program.
During the quarter, Nautilus initiated its Iterative Mapping Early Access Program with Baylor College of Medicine, advanced Tau proteoform assay work with collaborators, and appointed a new Vice President of Global Sales to drive early customer expansion ahead of full commercial launch.
Nautilus Biotechnology insider Sujal Patel now reports beneficial ownership of 21,249,965 shares of common stock, representing 16.3% of the company. This total includes shares he holds directly, through an LLC, through a children’s trust, and through stock options.
The filing explains that 10,366,721 shares are directly owned by Patel, 5,280,476 shares are held by PFV I, LLC, and 1,814,035 shares are held by the Sujal Patel 2020 Children's Trust, over which he and his spouse share voting and dispositive power. A further 3,788,733 shares are issuable upon exercise of options.
As of March 2, 2026, 2,326,231 of these option shares are exercisable within 60 days. On March 2, 2026 Patel received an option grant for 650,000 shares, and on March 4, 2026 he bought 25,000 shares of Nautilus Biotechnology common stock on the open market.
Parag Mallick filed Amendment No. 2 to update his beneficial ownership of Nautilus Biotechnology common stock. He reports beneficial ownership of 22,557,411 shares, representing 17.6% of the company’s common stock, based on 126,564,473 shares outstanding plus his option shares.
The total includes 20,493,392 shares held directly, options to purchase 1,864,019 shares, and 200,000 shares held by The Dream Finder Foundation over which he and his spouse share voting and dispositive power. On March 2, 2026, he was granted an additional option to buy 280,000 shares, with vesting subject to continued service and full acceleration upon certain change-in-control termination events.
Nautilus Biotechnology, Inc. director and CEO Sujal M. Patel reported an open-market purchase of 25,000 shares of Common Stock at a weighted average price of $2.6095 per share. Following this buy, he directly owns 10,366,721 common shares.
He also reports indirect ownership of 5,280,476 common shares held by PFV I, LLC, for which he is the manager, and 1,814,035 common shares held by the Sujal Patel 2020 Children's Trust, where he and his spouse serve as trustees.
Nautilus Biotechnology reported that its CFO and Treasurer, Anna Mowry, received a grant of stock options covering 160,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.
According to the award’s vesting terms, 25% of the options will vest on the one-year anniversary of the vesting commencement date of January 1, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months, contingent on her continued service as a “Service Provider.”